HPS
MCID: HNT002
MIFTS: 55

Hantavirus Pulmonary Syndrome (HPS)

Categories: Infectious diseases, Muscle diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Hantavirus Pulmonary Syndrome

MalaCards integrated aliases for Hantavirus Pulmonary Syndrome:

Name: Hantavirus Pulmonary Syndrome 12 20 58 29 3 44 15 17 71
Hps 20 3
Hantavirus-Associated Respiratory Distress Syndrome 20
Four Corners Hantavirus 20
Hanta Virus 71
Hantavirus 20
Hards 20

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:14472
MeSH 44 D018804
NCIt 50 C84747
SNOMED-CT 67 120639003
ICD10 32 B33.4
ICD10 via Orphanet 33 B33.4+ J17.1*
UMLS via Orphanet 72 C0243025
Orphanet 58 ORPHA319247
UMLS 71 C0243025 C0854421

Summaries for Hantavirus Pulmonary Syndrome

Disease Ontology : 12 A viral infectious disease that results in infection located in lung, has material basis in Sin Nombre virus, transmitted by deer mouse (Myodes glareolus), has material basis in Black Creek Canal virus, transmitted by cotton rat (Sigmodon hispidus), has material basis in Bayou virus, transmitted by marsh rice rat (Oryzomys palustris), has material basis in Laguna Negra virus, transmitted by small vesper mouse (Calomys laucha), or has material basis in Andes virus, transmitted by rice rat (Oligoryzomys longicaudatus). The infection has ymptom fever, has symptom muscle pain, has symptom headache, has symptom cough, has symptom vomiting, has symptom chills which rapidly progress to bilateral interstitial pulmonary infiltrates occurrence, pulmonary edema and hypoxia often resulting in death from shock or cardiac complications.

MalaCards based summary : Hantavirus Pulmonary Syndrome, also known as hps, is related to viral pneumonia and hemopericardium, and has symptoms including vomiting, cough and headache. An important gene associated with Hantavirus Pulmonary Syndrome is F3 (Coagulation Factor III, Tissue Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and PI3K-Akt signaling pathway. The drugs Ribavirin and Opicapone have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

GARD : 20 Hantavirus pulmonary syndrome (HPS) is a severe, respiratory disease caused by infection with a hantavirus. People can become infected with a hantavirus through contact with hantavirus-infected rodents or their saliva, urine and/or droppings. Early symptoms universally include fatigue, fever and muscle aches (especially in the thighs, hips, and/or back), and sometimes include headaches, dizziness, chills, and abdominal problems such as nausea, vomiting, diarrhea, and pain. Later symptoms of the syndrome occur 4 to 10 days after initial onset and include coughing and shortness of breath. HPS can be fatal; approximately 38% of individuals with HPS do not survive. There is no cure or specific treatment for HPS, but early diagnosis and treatment in intensive care may increase the chance of recovery.

CDC : 3 Hantaviruses are a family of viruses spread mainly by rodents and can cause varied disease syndromes in people worldwide. Infection with any hantavirus can produce hantavirus disease in people. Hantaviruses in the Americas are known as "New World" hantaviruses and may cause hantavirus pulmonary syndrome (HPS). Other hantaviruses, known as "Old World" hantaviruses, are found mostly in Europe and Asia and may cause hemorrhagic fever with renal syndrome (HFRS). Each hantavirus serotype has a specific rodent host species and is spread to people via aerosolized virus that is shed in urine, feces, and saliva, and less frequently by a bite from an infected host. The most important hantavirus in the United States that can cause HPS is the Sin Nombre virus, spread by the deer mouse.

Wikipedia : 74 Hantavirus pulmonary syndrome (HPS) is one of two potentially fatal syndromes of zoonotic origin caused... more...

Related Diseases for Hantavirus Pulmonary Syndrome

Diseases related to Hantavirus Pulmonary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 viral pneumonia 31.2 IFNB1 DDX58 CD8A
2 hemopericardium 30.5 F3 F2
3 respiratory failure 30.4 VEGFA LTA IL1A F3 F2 CD8A
4 dengue hemorrhagic fever 30.3 IFNB1 F3 F2
5 pericardial effusion 30.2 VEGFA F3 F2
6 thrombotic microangiopathy 30.0 VEGFA F3
7 thrombocytosis 29.9 IL1A F3 F2
8 portal hypertension 29.9 VEGFA F3 F2
9 crimean-congo hemorrhagic fever 29.8 IFNB1 F3 DDX58
10 yellow fever 29.8 LTA IL1A IFNB1 DDX58
11 exanthem 29.7 VEGFA SYK F3 F2 CD8A
12 bone inflammation disease 29.6 VEGFA IL1A CD8A
13 microvascular complications of diabetes 5 29.6 VEGFA KDR CDH5
14 autoimmune disease 29.5 SYK LTA IL1A IFNB1 F3
15 lassa fever 29.4 IRF3 DDX58 CD8A
16 lung disease 29.4 VEGFA IL1A F3 CD8A
17 thrombocytopenia 29.3 SYK LTA IL1A IFNB1 GZMB F3
18 hantavirus hemorrhagic fever with renal syndrome 29.3 VEGFA IFNB1 GZMB F3 DDX58 CDH5
19 pulmonary hypertension 29.2 VEGFA KDR IL1A F3 F2
20 japanese encephalitis 29.2 IRF3 IFNB1 DDX58
21 severe acute respiratory syndrome 29.2 IRF3 IFNB1 DDX58
22 viral infectious disease 28.9 IRF3 IFNB1 GZMB DDX58
23 hemorrhagic disease 28.6 VEGFA IRF3 IFNB1 F3 F2 DDX58
24 systemic lupus erythematosus 28.4 VEGFA SYK LYN LTA IRF3 IL1A
25 malaria 28.3 VEGFA LTA IL1A IFNB1 GZMB F3
26 hermansky-pudlak syndrome 11.6
27 hermansky-pudlak syndrome 2 11.4
28 hepatopulmonary syndrome 11.2
29 hermansky-pudlak syndrome 1 11.1
30 hermansky-pudlak syndrome 5 11.0
31 hermansky-pudlak syndrome with pulmonary fibrosis 11.0
32 hermansky-pudlak syndrome without pulmonary fibrosis 10.9
33 hermansky-pudlak syndrome 3 10.9
34 hermansky-pudlak syndrome 4 10.9
35 hermansky-pudlak syndrome 7 10.9
36 hermansky-pudlak syndrome 6 10.9
37 hermansky-pudlak syndrome 8 10.9
38 hermansky-pudlak syndrome 9 10.9
39 hermansky-pudlak syndrome 10 10.9
40 pulmonary edema 10.7
41 korean hemorrhagic fever 10.6
42 adult respiratory distress syndrome 10.5
43 prostatic hyperplasia, benign 10.5
44 prostatic hypertrophy 10.5
45 prostatic adenoma 10.5
46 acute kidney failure 10.5
47 proteinuria, chronic benign 10.5
48 achenbach syndrome 10.4 F3 F2
49 renal pelvis squamous cell carcinoma 10.4 F3 F2
50 synovial angioma 10.4 F3 F2

Graphical network of the top 20 diseases related to Hantavirus Pulmonary Syndrome:



Diseases related to Hantavirus Pulmonary Syndrome

Symptoms & Phenotypes for Hantavirus Pulmonary Syndrome

Symptoms:

12
  • vomiting
  • cough
  • headache
  • muscle pain
  • chills which rapidly progress to bilateral interstitial pulmonary infiltrates occurrence

MGI Mouse Phenotypes related to Hantavirus Pulmonary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CD8A CDH5 DDX58 F3 IFNB1 IL1A
2 homeostasis/metabolism MP:0005376 10.21 CDH5 DDX58 F2 F3 IFNB1 IL1A
3 cardiovascular system MP:0005385 10.16 CDH5 F2 F3 IL1A IRF3 KDR
4 cellular MP:0005384 10.13 CD8A CDH5 DDX58 F2 F3 IRF3
5 immune system MP:0005387 10.13 CD8A CDH5 DDX58 F2 F3 IFNB1
6 integument MP:0010771 9.96 CD8A CDH5 F2 F3 IL1A KDR
7 liver/biliary system MP:0005370 9.7 CDH5 DDX58 KDR LTA LYN SYK
8 nervous system MP:0003631 9.65 CD8A F2 F3 IFNB1 KDR LTA
9 respiratory system MP:0005388 9.23 F2 F3 IRF3 KDR LTA LYN

Drugs & Therapeutics for Hantavirus Pulmonary Syndrome

Drugs for Hantavirus Pulmonary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 555)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4 36791-04-5 37542
2
Opicapone Approved, Investigational Phase 4 923287-50-7
3
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
4
Lactitol Approved, Investigational Phase 4 585-86-4 157355
5
Levodopa Approved Phase 4 59-92-7 6047
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
9
Remifentanil Approved Phase 4 132875-61-7 60815
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
13
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
14
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
15
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
16
Empagliflozin Approved Phase 4 864070-44-0
17
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
18
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
19
Ethanol Approved Phase 4 64-17-5 702
20
Metformin Approved Phase 4 657-24-9 14219 4091
21
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
22
Canagliflozin Approved Phase 4 842133-18-0
23
Estazolam Approved, Illicit Phase 4 29975-16-4 3261
24
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
25
Lactulose Approved Phase 4 4618-18-2 11333
26
Iron Approved Phase 4 7439-89-6 23925 29936
27
Citalopram Approved Phase 4 59729-33-8 2771
28
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
29
Mycophenolic acid Approved Phase 4 24280-93-1 446541
30
Ferric maltol Approved Phase 4 33725-54-1
31
Saw palmetto Experimental, Investigational Phase 4
32
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
33 Parasympatholytics Phase 4
34 Tiotropium Bromide Phase 4 136310-93-5
35 Protein Kinase Inhibitors Phase 4
36 Albuterol Phase 4
37 Tocolytic Agents Phase 4
38 Catechol Phase 4
39 Antiparkinson Agents Phase 4
40 Narcotics Phase 4
41 Vasoconstrictor Agents Phase 4
42 Adrenergic alpha-1 Receptor Antagonists Phase 4
43 Adrenergic alpha-Antagonists Phase 4
44 Adrenergic Antagonists Phase 4
45 Dihydroxyphenylalanine Phase 4
46 Epinephryl borate Phase 4
47 Disinfectants Phase 4
48 Anti-Infective Agents, Local Phase 4
49 Saw palmetto extract Phase 4
50 Anesthetics, Local Phase 4

Interventional clinical trials:

(show top 50) (show all 684)
# Name Status NCT ID Phase Drugs
1 Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Study of DermaPure™ in Patients With "Hard to Heal" Chronic, Neuropathic Diabetic Foot Ulcers With Crossover Design for Standard Care Arm Unknown status NCT02081352 Phase 4
2 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
3 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients in Stable Conditions. Pilot Study Completed NCT01996124 Phase 4 Indacaterol Fumarate;Placebo
4 A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease Completed NCT03474081 Phase 4 FF/UMEC/VI;Tiotropium;Albuterol/salbutamol;Placebo to match FF/UMEC/VI;Placebo to match tiotropium
5 Pregabalin Has Additive Analgesic and Ventilatory Depressive Effects in Combination With Remifentanil Completed NCT01419405 Phase 4 Pregabalin;Remifentanil;sugar pill, saline infusion
6 Morphine for Palliative Treatment of Refractory Dyspnea in Patients With Advanced COPD: Benefits and Respiratory Adverse Effects Completed NCT02429050 Phase 4 sustained release morphine;placebo
7 Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients Completed NCT02432833 Phase 4 ENVARSUS®;PROGRAF®;ADVAGRAF®
8 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
9 Pilot, Randomised, Double-blind, Controlled Clinical Trial on the Combined Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel in the Reduction in Size and Change in Bioburden of Hard-to-heal Venous Leg Ulcers Completed NCT01153633 Phase 4
10 Immediate Implant Placement in the Posterior Region Combining Socket Seal Abutment and Alveolar Ridge Preservation: Implant, Hard and Soft Tissue Outcomes After 1 Year Completed NCT04553146 Phase 4
11 Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
12 Soft and Hard Tissue Stability After Immediate Tooth Replacement With Implant in Fresh Sockets Grafted With Different Soft Tissue Grafts Completed NCT02922075 Phase 4 Post operative medication
13 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
14 An Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation, Phase IV Trial Completed NCT01130636 Phase 4 Oseltamivir
15 Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA Completed NCT00351403 Phase 4 Ribavirin;Peginterferon alfa 2b
16 Effects of Photodynamic Therapy on Clinical and Immunological Parameters in a Group of Periodontal Patients Undergoing Supportive Periodontal Therapy Completed NCT02666573 Phase 4
17 A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
18 Pharmacokinetic Studies of Tacrolimus in Transplant Patients Completed NCT01889758 Phase 4 Prograf;Tacrolimus;Tacrolimus
19 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
20 Connective Tissue Graft vs Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects Randomized Controlled Clinical Trial Assessing Superiority in Health Related Quality of Life and Non-Inferiority in Root Coverage Completed NCT01440426 Phase 4
21 Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus Completed NCT02397421 Phase 4 Dapagliflozin;Placebo
22 A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis. Completed NCT01498887 Phase 4 Fingolimod (FTY720)
23 Comparison of Plasma Concentrations of Levobupivacaine With and Without Epinephrine for Transversus Abdominis Plane Block Under Ultrasound. Completed NCT01596998 Phase 4 Levobupivacaine with epinephrine;Levobupivacaine without epinephrine
24 A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT] Completed NCT03257358 Phase 4 Fingolimod
25 A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya® Completed NCT01705236 Phase 4 Fingolimod
26 Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training Completed NCT00922493 Phase 4
27 Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations Completed NCT02847442 Phase 4 BIA 9-1067;levodopa/dopa decarboxylase inhibitor
28 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV) Completed NCT01578213 Phase 4 Imatinib mesylate
29 Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure Completed NCT03226457 Phase 4 Empagliflozin 25mg;Placebo oral capsule;Frusemide
30 Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) Recruiting NCT04246619 Phase 4 Pregabalin;Duloxetine
31 An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib Recruiting NCT02584933 Phase 4 ceritinib
32 A Prospective, Multi-center, Open-labeled, Randomized Clinical Trial of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant Recipients to Compare QD Early Conversion and BID Tacrolimus Formulation. Recruiting NCT03216447 Phase 4 Advagraf;Prograf
33 TriMaster: Randomised Double-Blind Crossover Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes Who Have Suboptimal Glycaemic Control on Dual Therapy With Metformin and a Sulphonylurea Active, not recruiting NCT02653209 Phase 4 Sitagliptin - DPP4i;Canagliflozin - SGLT2i;Pioglitazone - TZD
34 The First Affiliated Hospital of Guangzhou University of Chinese Medicine Active, not recruiting NCT03997058 Phase 4 Oral estazolam medication
35 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
36 An Open, Randomized, Parallel Group, Single Center Study to Investigate the Effect of Lactulose Versus Plantago Ovate on the Quality of Life of Patients With Hard Stools and Hemorrhoids or Anal Fissure Terminated NCT00160290 Phase 4 Lactulose;Plantago ovata
37 A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression Terminated NCT01436643 Phase 4 Venlafaxine;Fluoxetine;Citalopram;Fingolimod
38 Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists Terminated NCT01108627 Phase 4 open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®;foradil placebo;foradil
39 A Randomized Open-label Study of Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis Terminated NCT03920059 Phase 4 Mycophenolate Mofetil
40 A Phase IV Study to Explore the Safety of ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency in Patients With Heart Failure Carrying Left Ventricular Assist Devices (ORION-LVAD-1) Terminated NCT03774615 Phase 4 Ferric maltol 30 mg (Feraccru®)
41 A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA.) COMPARED TO CYMBALTA (REGISTERED) MICROGRANULES (60 MG; ELI LILLY DO BRASIL LTDA) IN HEALTHY MALE RESEARCH SUBJECTS UNDER FED CONDITIONS Withdrawn NCT03794154 Phase 4 Cymbalta capsule;Duloxetine hydrochloride capsule
42 A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA) COMPARED WITH CYMBALTA(REGISTERED) ( 60 MG; ELI LILLY DO BRASIL LTDA) IN HEALTHY MALE RESEARCH SUBJECTS UNDER FASTED CONDITIONS Withdrawn NCT03729284 Phase 4 Cymbalta Capsules;Duloxetine Hydrochloride Capsules
43 A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY) Withdrawn NCT02090348 Phase 4 dimethyl fumarate
44 Double-blind, Randomised, Placebo-controlled Phase III Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults Unknown status NCT00581087 Phase 3 DHEA treatment;Placebo
45 Clinical Evidence Efficacy of a Mouthwash Containing Propolis for the Control of Plaque and Gingivitis: Phase III, Randomized, Double-blind Comparison With Mouthwash Chlorhexidine Base. Unknown status NCT01750801 Phase 3 Propolis;chlorhexidine
46 Bone Changes in Atrophic Maxilla Treated by Split-crest Technique and Dental Implants With Platelet Rich Fibrin and Nanobone® Versus Platelet Rich Fibrin Alone; Randomized Controlled Trial Unknown status NCT02836678 Phase 2, Phase 3
47 Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence Unknown status NCT01540656 Phase 3
48 A Multicenter, Randomized, Blinded, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control Completed NCT01490125 Phase 3 QVA149;Tiotropium;Placebo to QVA149;Placebo to tiotropium;Salbutamol/albuterol
49 A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea Completed NCT01598311 Phase 3 CB-183,315;Vancomycin;Placebo
50 Remaining Root Substance Comparing a New Ultrasonic Scaling Device, Hand Instrumentation and Subgingival Air Polishing With Glycine. An in Vivo and in Vitro Study Completed NCT02205619 Phase 2, Phase 3

Search NIH Clinical Center for Hantavirus Pulmonary Syndrome

Cochrane evidence based reviews: hantavirus pulmonary syndrome

Genetic Tests for Hantavirus Pulmonary Syndrome

Genetic tests related to Hantavirus Pulmonary Syndrome:

# Genetic test Affiliating Genes
1 Hantavirus Pulmonary Syndrome 29

Anatomical Context for Hantavirus Pulmonary Syndrome

MalaCards organs/tissues related to Hantavirus Pulmonary Syndrome:

40
Bone, Skin, Liver, Endothelial, Myeloid, Spinal Cord, Skeletal Muscle

Publications for Hantavirus Pulmonary Syndrome

Articles related to Hantavirus Pulmonary Syndrome:

(show top 50) (show all 683)
# Title Authors PMID Year
1
"Super-Spreaders" and Person-to-Person Transmission of Andes Virus in Argentina. 61
33264545 2020
2
Hantavirus pulmonary syndrome outbreaks associated with climate variability in Northwestern Argentina, 1997-2017. 61
33253144 2020
3
Hantavirus Infections-Treatment and Prevention. 61
33144850 2020
4
Orthohantaviruses, Emerging Zoonotic Pathogens. 61
32971887 2020
5
Hantavirus diseases pathophysiology, their diagnostic strategies and therapeutic approaches: A review. 61
32894790 2020
6
Home range variability, spatial aggregation, and excursions of Akodon azarae and Oligoryzomys flavescens in Pampean agroecosystems. 61
32304184 2020
7
Development of small-molecule inhibitors against hantaviruses. 61
32445882 2020
8
Atypical case of hantavirus infection in Sri Lanka mimicking leptospirosis: a case report. 61
32552909 2020
9
New data about home range and movements of Oligoryzomys flavescens (Rodentia: Cricetidae) help to understand the spread and transmission of Andes virus that causes Hantavirus Pulmonary Syndrome. 61
32034891 2020
10
Person-to-Person Transmission of Andes Virus in Hantavirus Pulmonary Syndrome, Argentina, 2014. 61
32186494 2020
11
Long-Term Rodent Surveillance after Outbreak of Hantavirus Infection, Yosemite National Park, California, USA, 2012. 61
32091360 2020
12
Hantavirus Infection with Renal Failure and Proteinuria, Colorado, USA, 2019. 61
31961310 2020
13
Hantavirus inhibits apoptosis by preventing mitochondrial membrane potential loss through up-regulation of the pro-survival factor BCL-2. 61
32032391 2020
14
Sociocultural determinants of adoption of preventive practices for hantavirus: A knowledge, attitudes, and practices survey in Tonosí, Panama. 61
32107494 2020
15
Hantavirus Infection Is Inhibited by Griffithsin in Cell Culture. 61
33251157 2020
16
Cryofixation of Inactivated Hantavirus-Infected Cells as a Method for Obtaining High-Quality Ultrastructural Preservation for Electron Microscopic Studies. 61
33240823 2020
17
Hantavirus Pulmonary Syndrome in Traveler Returning from Nepal to Spain. 61
31674901 2020
18
Development of RT-qPCR and semi-nested RT-PCR assays for molecular diagnosis of hantavirus pulmonary syndrome. 61
31877142 2019
19
Mechanisms of Hantavirus Transmission in Oligoryzomys longicaudatus. 61
31792647 2019
20
Detection of New World Hantavirus Antibodies in Rodents of Eastern New Mexico, USA. 61
31021684 2019
21
New Exposure Location for Hantavirus Pulmonary Syndrome Case, California, USA, 2018. 61
31538924 2019
22
Hantavirus Pulmonary Syndrome Risk in Entre Ríos, Argentina. 61
31338625 2019
23
Notes from the Field: Hantavirus Pulmonary Syndrome - Denver, Colorado, 2018. 61
31487276 2019
24
Dendritic Cells (DCs) as "Fire Accelerants" of Hantaviral Pathogenesis. 61
31540199 2019
25
Current Situation and Perspectives on Hantaviruses in Mexico. 61
31336858 2019
26
Epidemiological description, case-fatality rate, and trends of Hantavirus Pulmonary Syndrome: 9 years of surveillance in Argentina. 61
30840775 2019
27
Progress on the Prevention and Treatment of Hantavirus Disease. 61
31277410 2019
28
Malaria and Hantavirus Pulmonary Syndrome in Gold Mining in the Amazon Region, Brazil. 61
31130600 2019
29
Serum Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. 61
30698699 2019
30
[HANTAVIRUS PULMONARY SYNDROME DIAGNOSED IN A RETURNED TRAVELER FROM THE USA]. 61
31104390 2019
31
Unique Interferon Pathway Regulation by the Andes Virus Nucleocapsid Protein Is Conferred by Phosphorylation of Serine 386. 61
30867297 2019
32
Innate and adaptive immune responses against human Puumala virus infection: immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus-associated syndromes. 61
30663801 2019
33
Capillary leak-syndrome triggered by Maripa virus in French Guiana: case report and implication for pathogenesis. 61
30876401 2019
34
The ecological dynamics of hantavirus diseases: From environmental variability to disease prevention largely based on data from China. 61
30789905 2019
35
Two Point Mutations in Old World Hantavirus Glycoproteins Afford the Generation of Highly Infectious Recombinant Vesicular Stomatitis Virus Vectors. 61
30622188 2019
36
Orthohantaviruses belonging to three phylogroups all inhibit apoptosis in infected target cells. 61
30696898 2019
37
Hantavirus entry: Perspectives and recent advances. 61
31439149 2019
38
Hantavirus pulmonary syndrome in children: case report and case series from an endemic area of Brazil. 61
31859842 2019
39
Immunocytochemical and Ultrastructural Evidence Supporting That Andes Hantavirus (ANDV) Is Transmitted Person-to-Person Through the Respiratory and/or Salivary Pathways. 61
31998273 2019
40
Expansion of the range of Necromys lasiurus (Lund, 1841) into open areas of the Atlantic Forest biome in Rio de Janeiro state, Brazil, and the role of the species as a host of the hantavirus. 61
30149024 2018
41
Protocadherin-1 is essential for cell entry by New World hantaviruses. 61
30464266 2018
42
Notes from the Field: Exported Case of Sin Nombre Hantavirus Pulmonary Syndrome - Israel, 2017. 61
30307906 2018
43
Maripa Virus RNA Load and Antibody Response in Hantavirus Pulmonary Syndrome, French Guiana. 61
30124408 2018
44
Complete Genome Sequences of Monongahela Hantavirus from Pennsylvania, USA. 61
30533642 2018
45
Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections. 61
30067171 2018
46
Rats! Hantavirus: A Case Report of a Suspected Case in Eastern Tennessee. 61
30010530 2018
47
Distributional ecology of Andes hantavirus: a macroecological approach. 61
29929522 2018
48
Space Use and Social Mating System of the Hantavirus Host, Oligoryzomys longicaudatus. 61
29196828 2018
49
Habitat, species richness and hantaviruses of sigmodontine rodents within the Interior Atlantic Forest, Paraguay. 61
30067840 2018
50
[Outbreak of hantavirus pulmonary syndrome in Tucumán, Argentina]. 61
29940540 2018

Variations for Hantavirus Pulmonary Syndrome

Expression for Hantavirus Pulmonary Syndrome

Search GEO for disease gene expression data for Hantavirus Pulmonary Syndrome.

Pathways for Hantavirus Pulmonary Syndrome

Pathways related to Hantavirus Pulmonary Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 VEGFA SYK LYN IRF3 IFNB1 F3
2
Show member pathways
12.79 VEGFA SYK KDR IRF3 IFNB1
3
Show member pathways
12.73 VEGFA SYK LYN IRF3 IFNB1
4
Show member pathways
12.67 VEGFA SYK LYN LTA IRF3 IL1A
5
Show member pathways
12.62 VEGFA LTA IL1A GZMB CD8A
6 12.55 SYK LTA IRF3 IFNB1 DDX58
7
Show member pathways
12.44 SYK LYN IRF3 IL1A IFNB1 DDX58
8
Show member pathways
12.4 VEGFA SYK LYN KDR
9
Show member pathways
12.01 LTA KDR IRF3 IL1A IFNB1
10
Show member pathways
11.93 VEGFA SYK LYN KDR GZMB
11 11.89 SYK IL1A IFNB1
12 11.87 SYK LYN F2
13
Show member pathways
11.83 VEGFA KDR CDH5
14
Show member pathways
11.82 VEGFA LYN KDR
15 11.81 VEGFA KDR IL1A CDH5
16 11.72 VEGFA IL1A F3
17
Show member pathways
11.66 VEGFA KDR CDH5
18 11.64 KDR F3 CDH5
19 11.64 SYK LYN LTA DDX58
20 11.61 SYK LYN IRF3 GZMB DDX58 CD8A
21 11.57 LTA GZMB CD8A
22 10.86 SYK LYN
23
Show member pathways
10.78 VEGFA KDR

GO Terms for Hantavirus Pulmonary Syndrome

Cellular components related to Hantavirus Pulmonary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 SYK ROBO4 PCDH1 LYN LTA KDR
2 extracellular region GO:0005576 9.28 VEGFA LTA KDR IL1A IFNB1 GZMB

Biological processes related to Hantavirus Pulmonary Syndrome according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 10 SYK LYN KDR IRF3 DDX58
2 positive regulation of gene expression GO:0010628 9.96 VEGFA IL1A F3 DDX58 CDH5
3 cell surface receptor signaling pathway GO:0007166 9.93 SYK IFNB1 F2 CD8A
4 cytokine-mediated signaling pathway GO:0019221 9.92 VEGFA IL1A IFNB1 F3
5 angiogenesis GO:0001525 9.88 VEGFA SYK ROBO4 KDR
6 positive regulation of protein phosphorylation GO:0001934 9.84 VEGFA LYN KDR F2
7 platelet activation GO:0030168 9.81 SYK LYN F2
8 blood coagulation GO:0007596 9.81 LYN IFNB1 F3 F2
9 positive regulation of interleukin-6 production GO:0032755 9.79 SYK IL1A DDX58
10 positive regulation of tumor necrosis factor production GO:0032760 9.78 SYK IL1A DDX58
11 positive regulation of endothelial cell proliferation GO:0001938 9.74 VEGFA KDR F3
12 positive regulation of cell migration GO:0030335 9.72 VEGFA LYN KDR F3 CDH5
13 positive regulation of interleukin-8 production GO:0032757 9.7 SYK F3 DDX58
14 positive regulation of protein complex assembly GO:0031334 9.67 VEGFA SYK CDH5
15 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 SYK LYN KDR CD8A
16 positive regulation of glial cell proliferation GO:0060252 9.64 LYN LTA
17 vascular endothelial growth factor signaling pathway GO:0038084 9.64 VEGFA KDR
18 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.62 SYK DDX58
19 response to exogenous dsRNA GO:0043330 9.61 IRF3 IFNB1 DDX58
20 positive regulation of cellular component movement GO:0051272 9.59 VEGFA LYN
21 vascular wound healing GO:0061042 9.58 VEGFA KDR
22 peptidyl-tyrosine autophosphorylation GO:0038083 9.58 SYK LYN KDR
23 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 VEGFA LYN KDR F2
24 regulation of platelet aggregation GO:0090330 9.55 SYK LYN
25 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.48 VEGFA KDR
26 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.46 VEGFA KDR
27 cellular response to exogenous dsRNA GO:0071360 9.33 IRF3 IFNB1 DDX58
28 positive regulation of positive chemotaxis GO:0050927 9.13 VEGFA KDR F3
29 positive regulation of angiogenesis GO:0045766 9.02 VEGFA KDR IL1A F3 CDH5

Molecular functions related to Hantavirus Pulmonary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.5 SYK LYN KDR
2 platelet-derived growth factor receptor binding GO:0005161 9.26 VEGFA LYN
3 cytokine activity GO:0005125 9.26 VEGFA LTA IL1A IFNB1
4 vascular endothelial growth factor receptor 2 binding GO:0043184 9.16 VEGFA CDH5
5 signaling receptor binding GO:0005102 9.02 SYK LYN LTA F2 CDH5

Sources for Hantavirus Pulmonary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....